Intellia's in vivo CRISPR therapy first to succeed in Phase 3
An experimental treatment that uses CRISPR to edit genes directly inside the body has just succeeded in a Phase 3 trial — a first for the technology — putting it on track for a potential FDA approval ...
April 27, 2026 07:01 AM EDTUpdated 07:33 AM R&DCell/Gene Tx Intellia's in vivo CRISPR therapy first to succeed in Phase 3 Lei Lei Wu News Reporter Ryan Cross Senior Science Correspondent An experimental treatment that uses CRISPR to edit genes directly inside the body has just succeeded in a Phase 3 trial — a first for the … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that